Canurta Naturals to Lead Operational Transition at FSOil Facility, Expanding cGMP Botanical Extraction Capacity in North America

Toronto, ON — January 12, 2025 – Canurta Naturals today announced that it has reached an agreement under which it will manage operation of FSOil’s large-scale botanical extraction facilities in Woodburn, Oregon. Under this new structure, the processing facility, select equipment, and key operational personnel will continue their work under Canurta Naturals, ensuring exceptional and consistent services for existing customers while strengthening North American supply of high-quality botanical ingredients.

Canurta Naturals USA will operate the cGMP CO₂ extraction and post-processing facilities in the Willamette Valley, with both supercritical and subcritical capabilities and certifications that include Current Good Manufacturing Practices, USDA Organic, U.S. Hemp Authority, and Kosher. Since 2017, FSOil has provided toll processing, bulk extracts, and finished product development for hemp and other plant-based functional ingredients.

By integrating the manufacturing platform and experienced team, Canurta Naturals will expand its ability to deliver validated, science-first nutraceuticals focused on inflammation and cognitive health, and have the ability to improve extraction techniques to produce products which include rare hemp polyphenols such as cannflavins A and B. The transition is designed to maintain service for current customers while adding new capabilities in formulation, R&D, and commercialization. 

Existing customers will continue to be served by the same core operational team and facility in Woodburn, Oregon. Day-to-day production, quality systems, and service offerings—including CO₂ extraction, winterization, distillation, remediation, blending, and formulation—will continue, with additional support from Canurta Naturals’ product development and regulatory teams. 

Over time, the integrated operation is expected to expand beyond hemp into additional botanicals, supporting Canurta Naturals’ strategy to unlock under-utilized plant compounds for evidence-based nutraceuticals targeting inflammation, cognition, stress, and healthy aging. 

“Our priority has always been our customers and the integrity of the products made here. This operational transition ensures continuity, quality, and reliability, while honoring the work that went into building this platform. It’s rewarding to see the foundation we created continue to support customers and the industry,” said, Kathryn Ward, Chief Operating Officer of Canurta Naturals USA.  

Akeem Gardner, CEO of Canurta Inc added, “this integration strengthens our manufacturing backbone in North America and aligns with Canurta’s science-first approach to botanical development. Preserving operational excellence while expanding R&D, formulation, and regulatory capabilities was the priority—and this platform allows us to do exactly that.” 

About Canurta Naturals USA Inc. 

Canurta Naturals develops science-first nutraceuticals focused on cognitive and inflammatory health. By harnessing rare botanicals and patented technologies that unlock bioactive hemp polyphenols such as cannflavins A and B, Canurta Naturals delivers safe, clinically relevant products aimed at supporting inflammation, brain health, stress resilience, and everyday wellness. 

About Canurta Inc. 

Canurta Inc is an innovative biotechnology company dedicated to pioneering botanical therapeutics for inflammatory and neurodegenerative diseases. Utilizing its proprietary Polykye™ platform, Canurta develops rare bioactive botanical ingredients and multi-target formulations designed to address complex disease mechanisms with clinical rigor. The company's lead candidate, CNR-401, is advancing towards Phase 2 clinical trials targeting Amyotrophic Lateral Sclerosis (ALS), with a parallel strategy incorporating real-world evidence initiatives to accelerate global regulatory approval. 

For further information, please contact:
 Akeem Gardner, CEO of Canurta Inc akeem@canurta.com